Jerusalem factory for Universal Flu vaccine

Israeli biotech Biondvax is to receive a Government grant for 20% of the NIS 20 million required to build a Jerusalem factory for commercial scale production of its M-001 Universal Flu vaccine.  Biondvax plans to produce tens of millions of doses of M-001 annually, including for Phase 3 trials.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *